Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€15.12

€15.12

-0.850%
-0.13
-0.850%
-
 
30.06.25 / Tradegate WKN: A140ML / Name: Novocure / Stock / Biotechnology & Medical Research / Mid Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Novocure Ltd Stock

The price for the Novocure Ltd stock decreased slightly today. Compared to yesterday there is a change of -€0.130 (-0.850%).
Our community identified positive and negative aspects for Novocure Ltd stock for the coming years. 1 users see the criterium "Shareholder structure" as a plus for the Novocure Ltd stock. On the other hand our users think that "EBIT growth" could be a problem in the future.

Pros and Cons of Novocure Ltd in the next few years

Pros
?
W********* I********* f** t** n*** y****
?
B****
?
C******** o* t** e**********
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Novocure Ltd vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Novocure Ltd -0.850% 5.331% -10.217% -8.227% -48.094% -77.223% -71.373%
Ironwood Pharmaceuticals 1.690% 4.202% 12.727% -89.217% -85.238% -94.341% -93.111%
Arrowhead Pharmaceuticals Inc. -1.010% 0.075% -5.125% -44.637% -27.440% -60.048% -65.061%
Iovance Biotherapeutics Inc. 4.140% -9.099% -5.739% -80.618% -79.024% -86.246% -94.076%

News

Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025
Novocure to Present Final Secondary Endpoint Data from the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) in Pancreatic Cancer at the ESMO Gastrointestinal Cancers Congress 2025


Novocure (NASDAQ: NVCR) announced today that it will present the final secondary endpoint results from the Phase 3 PANOVA-3 trial of its Tumor Treating Fields (TTFields) therapy for unresectable

Novocure to Report Second Quarter 2025 Financial Results
Novocure to Report Second Quarter 2025 Financial Results


Novocure (NASDAQ: NVCR) will report financial results for the second quarter 2025 on July 24, 2025, before the U.S. financial markets open.



Novocure management will host a conference call and

Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting


Novocure (NASDAQ: NVCR) announced that results from the Phase 3 PANOVA-3 trial of Tumor Treating Fields (TTFields) therapy for pancreatic cancer will be presented today at the 2025 American Society